A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous (i.v.) Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Male osteoporosis; Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 06 Apr 2017 Planned End Date changed from 1 Dec 2018 to 16 Apr 2018.
- 06 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 16 Apr 2018.